Evidence mapPaperPMID 41827253Full record

ReviewJournal of clinical medicine2026

Advances in Medicalized Hair Loss Solutions: A Review of Current Clinical Practices and Regenerative Medicine-Based Protocols with Focus on Off-Label Injectable Treatments.

Angelica Ferro, Mohammad Alkhowailed, Alexandre Porcello, Marco Cerrano, Michèle Chemali, Kelly Lourenço, Cíntia Marques, Wassim Raffoul, Lee Ann Applegate, Alexis E Laurent

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Angelica FerroDevelopment Department, LOUNA REGENERATIVE SA, CH-1207 Geneva, Switzerland.
Mohammad AlkhowailedDepartment of Dermatology, College of Medicine, Qassim University, Buraidah 52571, Saudi Arabia.
Alexandre PorcelloDevelopment Department, LOUNA REGENERATIVE SA, CH-1207 Geneva, Switzerland.ORCID 0000-0003-1603-2704
Marco CerranoAesthetic Surgery Department, Entourage Aesthetic Clinic, CH-1003 Lausanne, Switzerland.ORCID 0009-0006-0093-8826
Michèle ChemaliPlastic and Aesthetic Surgery Service, Centre Médical Lausanne Ouest, CH-1008 Prilly, Switzerland.
Kelly LourençoDevelopment Department, LOUNA REGENERATIVE SA, CH-1207 Geneva, Switzerland.
Cíntia MarquesDevelopment Department, LOUNA REGENERATIVE SA, CH-1207 Geneva, Switzerland.
Wassim RaffoulPlastic and Reconstructive Surgery, Ensemble Hospitalier de la Côte, CH-1110 Morges, Switzerland.ORCID 0009-0005-8916-9463
Lee Ann ApplegateFaculty of Biology and Medicine, University of Lausanne, CH-1015 Lausanne, Switzerland.ORCID 0000-0002-7346-9921
Alexis E LaurentManufacturing Department, LAM Biotechnologies SA, CH-1066 Epalinges, Switzerland.ORCID 0000-0001-5738-8702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hair loss, or alopecia, constitutes a significant and prevalent concern affecting individuals worldwide. Despite the availability of numerous commercial solutions, many individuals continue to experience substantial psychological distress, leading to adverse impact on personal relationships, social interactions, and occupational performance. The limitations of conventional treatments, such as oral medication with potential systemic side effects and topical applications with localized adverse events, have driven the exploration of alternative therapies. Emerging localized injectable treatments for hair regrowth (PRP, stem cells, exosomes) offer a promising avenue for addressing this persistent issue. These injectable therapies hold the potential to minimize the systemic side effects often associated with oral medications, while also mitigating the localized adverse events that can arise from topical applications. This narrative review provides a comprehensive overview of the medical state-of-the-art in off-label injectable hair regrowth treatments, delving into the diverse range of available options. A critical component of this narrative review involves a thorough evaluation of relevant clinical studies, assessing the efficacy and safety profiles of these emerging therapies. Furthermore, detailed attention is given to injection techniques and administration protocols, crucial factors in optimizing treatment outcomes. These evolving therapies represent a significant advancement in the field of scalp regenerative medicine. By stimulating hair follicle reactivation, these treatments aim to promote sustained and natural hair growth, providing individuals with more effective and durable solutions. The enhanced safety profiles of these injectable therapies, compared to conventional systemic pharmacological treatments (minoxidil, finasteride), offer a substantial improvement in patient care, addressing a widespread clinical need.

Indexed as

alopeciaclinical studieshair follicle reactivationhair losshair regrowthinjectable treatmentsoff-label treatmentsregenerative medicinetreatment protocols

Identifiers

PMID41827253
PMCPMC12985832

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.